Preexisting immunity, not frailty phenotype, predicts influenza postvaccination titers among older veterans

Clinical and Vaccine Immunology

Volumn 24, Issue 3, 2017, Pages

  Van Epps, Puja ^a,b   Tumpey, Terrence ^c   Pearce, Melissa B ^c   Golding, Hana ^d   Higgins, Patricia ^a,e   Hornick, Thomas ^a,b   Burant, Christopher ^a,e   Wilson, Brigid M ^a   Banks, Richard ^b   Gravenstein, Stefan ^a,b   Canaday, David H ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Frailty; Influenza vaccines

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; AFRICAN AMERICAN; AGED; AGING; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; FRAILTY; FUNCTIONAL STATUS; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MICRONEUTRALIZATION ASSAY; MORBIDITY; MORTALITY RISK; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SEASONAL INFLUENZA; VETERAN; VIRUS STRAIN; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; SERODIAGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VETERANS;

EID: 85017538557     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00498-16     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. 2010. Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep 59:1057-1062.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. https://doi.org/10.1001/jama.289.2.179.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340. https://doi.org/10.1001/jama.292.11.1333.
4. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, Black S, Shay DK. 2007. Influenza- and RSV-associated hospitalizations among adults. Vaccine 25:846-855. https://doi.org/10.1016/j.vaccine.2006.09.041.
5. Sambhara S, McElhaney JE. 2009. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 333:413-429. https://doi.org/10.1007/978-3-540-92165-3-20.
6. Lang PO, Govind S, Bokum AT, Kenny N, Matas E, Pitts D, Aspinall R. 2013. Immune senescence and vaccination in the elderly. Curr Top Med Chem 13:2541-2550. https://doi.org/10.2174/15680266113136660181.
7. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. 2009. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 21:201-209. https://doi.org/10.1007/BF03324904.
8. Liu WM, Van Der Zeijst BA, Boog CJ, Soethout EC. 2011. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin 7(Suppl):94-98. https://doi.org/10.4161/hv. 7.0.14568.
9. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. 2003. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348:1322-1332. https://doi.org/10.1056/NEJMoa025028.
10. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. 1994. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331:778-784. https://doi.org/10.1056/NEJM199409223311206.
11. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. 2005. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165:265-272. https://doi.org/10.1001/archinte.165.3.265.
12. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. 2008. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested casecontrol study. Lancet 372:398-405. https://doi.org/10.1016/S0140-6736 (08) 61160-5.
13. Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S. 2015. Preexisting immunity, more than aging, influences influenza vaccine responses. Open Forum Infect Dis 2: ofv052. https://doi.org/10.1093/ofid/ofv052.
14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. 2001. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-M156. https://doi.org/10.1093/gerona/56.3. M146.
15. Wang GC, Casolaro V. 2014. Immunologic changes in frail older adults. Transl Med UniSa 9:1-6.
16. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK. 2009. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 8:18-25. https://doi.org/10.1111/j.1474-9726.2008.00443.x.
17. Compte N, Zouaoui Boudjeltia K, Vanhaeverbeek M, De Breucker S, Tassignon J, Trelcat A, Pepersack T, Goriely S. 2013. Frailty in old age is associated with decreased interleukin-12/23 production in response to Toll-like receptor ligation. PLoS One 8:e65325. https://doi.org/10.1371/journal.pone.0065325.
18. Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. 2013. Functional status of older nursing home residents can affect the efficacy of influenza vaccination. J Gerontol A Biol Sci Med Sci 68:324-330. https://doi.org/10.1093/gerona/gls175.
19. Yao X, Hamilton RG, Weng NP, Xue QL, Bream JH, Li H, Tian J, Yeh SH, Resnick B, Xu X, Walston J, Fried LP, Leng SX. 2011. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 29:5015-5021. https://doi.org/10.1016/j.vaccine.2011.04.077.
20. Ridda I, Macintyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, McIntyre PB. 2009. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27:1628-1636. https://doi.org/10.1016/j.vaccine.2008.11.098.
21. Centers for Disease Control and Prevention. 2010. Update: influenza activity: United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 59:901-908.
22. Thompson MG, Naleway A, Fry AM, Ball S, Spencer SM, Reynolds S, Bozeman S, Levine M, Katz JM, Gaglani M. 2016. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine 34:981-988. https://doi.org/10.1016/j.vaccine.2015.10.119.
23. Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, Vandermause M, Lindstrom S, Kempf D, Shay DK. 2010. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 304:1091-1098. https://doi.org/10.1001/jama.2010.1277.
24. Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. 2016. Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin Vaccine Immunol 23:228-235. https://doi.org/10.1128/CVI.00604-15.
25. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, Averhoff F, Chaves SS, Gargiullo P, Bridges CB. 2007. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine 25:154-160. https://doi.org/10.1016/j.vaccine.2006.05.129.
26. Mosterin Hopping A, McElhaney J, Fonville JM, Powers DC, Beyer WE, Smith DJ. 2016. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine 34:540-546. https://doi.org/10.1016/j.vaccine.2015.11.058.
27. Centers for Disease Control and Prevention. 2011. Update: influenza activity: United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 60:705-712.
28. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M. 2014. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 210:126-137. https://doi.org/10.1093/infdis/jiu048.
29. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361:1945-1952. https://doi.org/10.1056/NEJMoa0906453.
30. Gaglani M, Spencer S, Ball S, Song J, Naleway A, Henkle E, Bozeman S, Reynolds S, Sessions W, Hancock K, Thompson M. 2014. Antibody response to influenza A (H1N1) pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis 209:1705-1714. https://doi.org/10.1093/infdis/jit825.
31. Fried LP, Bandeen-Roche K, Chaves PH, Johnson BA. 2000. Preclinical mobility disability predicts incident mobility disability in older women. J Gerontol A Biol Sci Med Sci 55:M43-M52. https://doi.org/10.1093/gerona/55.1. M43.
32. Orme JG, Reis J, Herz EJ. 1986. Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol 42:28-33. https://doi.org/10.1002/1097-4679 (198601) 42:1<28:: AID-JCLP2270420104>3.0. CO;2-T.
33. Taylor HL, Jacobs DR, Jr, Schucker B, Knudsen J, Leon AS, Debacker G. 1978. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31:741-755. https://doi.org/10.1016/0021-9681 (78) 90058-9.
34. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br Med Bull 35:69-75.
35. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777. https://doi.org/10.1017/S0022172400022610.
36. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24:157-160.
37. Faix DJ, Hawksworth AW, Myers CA, Hansen CJ, Ortiguerra RG, Halpin R, Wentworth D, Pacha LA, Schwartz EG, Garcia SM, Eick-Cost AA, Clagett CD, Khurana S, Golding H, Blair PJ. 2012. Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses. PLoS One 7:e34581. https://doi.org/10.1371/journal.pone.0034581.
38. Hsu JP, Zhao X, Chen MI, Cook AR, Lee V, Lim WY, Tan L, Barr IG, Jiang L, Tan CL, Phoon MC, Cui L, Lin R, Leo YS, Chow VT. 2014. Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. BMC Infect Dis 14:414. https://doi.org/10.1186/1471-2334-14-414.
39. Grund S, Adams O, Wahlisch S, Schweiger B. 2011. Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. J Virol Methods 171:369-373. https://doi.org/10.1016/j.jviromet.2010.11.024.
40. Verschoor CP, Singh P, Russell ML, Bowdish DM, Brewer A, Cyr L, Ward BJ, Loeb M. 2015. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One 10:e0131531. https://doi.org/10.1371/journal.pone.0131531.
41. Noah DL, Hill H, Hines D, White EL, Wolff MC. 2009. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 16:558-566. https://doi.org/10.1128/CVI.00368-08.